Navigation Links
vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

Six-Month Follow-Up Shows Reduced Stenosis, Healthy Endothelial Regrowth in Vessel Treated Proactively for Vulnerable Plaque

DOYLESTOWN, Pa., June 1 /PRNewswire/ -- Six months after placement of a vProtect(TM) Luminal Shield to treat a "vulnerable" plaque, a follow-up exam revealed reduced plaque burden and reduced stenosis in the target vessel. The exam was part of the SECRITT I trial, a randomized study designed to evaluate the vProtect(TM) Luminal Shield as a prophylactic treatment for non-flow-limiting vulnerable plaques. The SECRITT I trial is sponsored and conducted by Erasmus University in Rotterdam. The 6-month follow-up exam was performed on May 20 by an interventional cardiology team led by Professor Patrick Serruys, the principal investigator for the SECRITT I study. Evelyn Regar, MD, PhD moderated the case at the EuroPCR congress in Barcelona. The vProtect(TM) Luminal Shield is manufactured by Prescient Medical, which plans to pursue a vulnerable plaque indication in the future.

The patient, a 75-year-old woman, was treated six months earlier for a culprit lesion in the left anterior descending coronary artery. At that time the SECRITT investigators, using a combination of imaging techniques, also located a vulnerable plaque in the patient's left circumflex artery. The lesion was unremarkable by angiography (37% diameter stenosis); such lesions are usually not treated, even though vulnerable plaques are prone to rupture with potentially fatal consequences. A 3.5 mm vProtect(TM) Luminal Shield was placed in the vessel (reference vessel diameter 2.74 mm), resulting in a post-procedural stenosis of 30%.

The 6-month angiographic follow-up exam was performed per study protocol using a variety of imaging techniques: multi-slice CT, intravascular ultrasound (IVUS), IVUS-virtual histology (IVUS-VH), angiography, and optical coherence tomography (OCT). Additional details on the SECRITT I study methodology can be found in a case study published recently in Nature Reviews Cardiology (vol. 6, May 2009).

The follow-up exam indicated that the self-expanding vProtect(TM) Luminal Shield had stabilized the vulnerable lesion while gently expanding over time. Imaging studies revealed that the residual stenosis in the area of the lesion improved from 30% to just 5% (measured by Quantitative Angiography). The Shield was covered by a thin layer of healthy tissue with an average thickness of 80 - 110 microns. "These results are comparable to what is seen with drug eluting stents in terms of thickness--we did not see a significant hyperplastic injury response," commented cardiac pathologist Gary Tearney, MD, PhD. Dr. Tearney, an Associate Professor of Pathology at Harvard University and the Wellman Center for Photomedicine, went on to explain that "The Shield appears to be perfectly designed for just this type of lesion--since it's self-expanding, there is less chance of rupturing the plaque."

Prescient Medical views the SECRITT I trial as a significant step toward achieving its mission of reducing deaths from heart attacks. According to Prescient CEO Patricia Scheller, "In the future, we hope that the Shield will be used to stabilize these soft, rupture-prone lesions without causing excessive injury to the vessel wall like traditional balloon-expandable stents. We are very encouraged by the healthy endothelial tissue coverage and reduced stenosis demonstrated in this patient."

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at or call +1-866-376-0500.

SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
2. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Doctors Urge Precaution to Shield Against Swine Flu
6. NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device
7. Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup
8. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
11. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Post Your Comments:
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... New York , 24. November 2015 ... des Avery Breathing Pacemaker Systems, ist erfreut, ... als Clinical Consultant bekannt geben zu können. ...   --> Foto ... Stockholm (Schweden). Von 1984-1986 war ...
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... ... SCOTTSDALE, AZ) - Today, Dr. Todd C. Hobgood ... non-surgical treatments, announced the expansion of his private practice capabilities with the grand ... trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves the ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted ... in Chicago, IL, UV Angel is evaluating the efficacy of its product and its ... units (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... scholarships for people struggling with eating disorders as a result of the $20,000 ... annual event, held at Fox Run Golf Club in Eureka, will help individuals ...
(Date:11/25/2015)... Davie, Florida (PRWEB) , ... November 25, 2015 ... ... PharmaTech LLC has announced that it has undertaken significant expansion of its current ... Florida. The investment is part of PharmaTech’s strategy to increase its manufacturing capacity ...
Breaking Medicine News(10 mins):